Answers are grounded in this paper and cite their sources.
Interleukin-2 (IL-2), which is a growth factor for T lymphocytes, can also sometimes be inhibitory. Thus, the proliferation of CD8 + T cells in vivo is increased after the injection of a monoclonal antibody that is specific for IL-2 (IL-2 mAb), perhaps reflecting the removal of IL-2–dependent CD4 + T regulatory cells (T regs). Instead, we show here that IL-2 mAb augments the proliferation of CD8 + cells in mice simply by increasing the biological activity of preexisting IL-2 through the formation of immune complexes. When coupled with recombinant IL-2, some IL-2/IL-2 mAb complexes cause massive (>100-fold) expansion of CD8 + cells in vivo, whereas others selectively stimulate CD4 + T regs. Thus, different cytokine-antibody complexes can be used to selectively boost or inhibit the immune response.
No takes yet. Share an insight, caveat, or question.
Boyman et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: